$APTO News

Last published 11mo ago

11mo agoAPTOAptose's Tuspetinib Triple Drug Therapy Featured at the 2025 ASH Annual Meeting; High Rate of Frontline Clinical Responses Continues Across AML PopulationsGlobeNewswireTUS+VEN+AZA triplet frontline therapy demonstrates high rates of efficacy and MRD-negative remissions in newly diagnosed AML patients with diverse mutationsSafety continues to be a notable hallmark of TUS-based
1y agoAPTOAptose Announces Auditor Not Standing for Re-AppointmentGlobeNewswireSAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug
1y agoAPTOAptose to Present at the 2025 Bloom Burton & Co. Healthcare Investor ConferenceGlobeNewswireSAN DIEGO and TORONTO, April 23, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based triple drug
1y agoAPTOAptose Common Shares to Delist from Nasdaq as of April 2, 2025GlobeNewswireSAN DIEGO and TORONTO, April 01, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing a tuspetinib (TUS) based
1y agoAPTOAptose Reports Year End 2024 Results and Corporate HighlightsGlobeNewswireTuspetinib Triple Drug Frontline Therapy Advancing in TUSCANY Clinical Trial Results to Date Highlight TUS Potential as an Ideal Third Drug to Include in AML Triplet Therapy Aptose Signs Debt Conversion
1y agoAPTOAptose Biosciences Meets Nasdaq Minimum Bid Price ComplianceGlobeNewswireSAN DIEGO and TORONTO, March 17, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based
1y agoAPTOAptose Announces Positive Clinical Safety Review Committee (CSRC) Approval to Dose Escalate in Phase 1/2 Tuscany Trial of Frontline Triple Drug Therapy with Tuspetinib Amid Complete Responses and Favorable Safety in First CohortGlobeNewswireTUS+VEN+AZA triplet achieves complete responses (CRs) in difficult-to-treat TP53-mutated/CK AML and FLT3-wildtype AML patients, including a measurable residual disease (MRD) negative remission Dosing of initial 40 mg
1y agoAPTOAptose Announces Reverse Share SplitGlobeNewswireSAN DIEGO and TORONTO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based
1y agoAPTOAptose Enters into $25 Million Committed Equity Facility and Establishes New At-The-Market FacilityGlobeNewswireSAN DIEGO and TORONTO, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing the tuspetinib (TUS)-based
1y agoAPTOAptose's Frontline Triple Drug Therapy with Tuspetinib Achieves Notable Responses in Newly Diagnosed AML Patients in the Phase 1/2 TUSCANY TrialGlobeNewswireTUS+VEN+AZA triplet achieves Cycle 1 complete remission (CR) in TP53-mutated/CK AMLTUS+VEN+AZA triplet achieves Cycle 1 complete remissions in FLT3-wildtype AML patientsTUS+VEN+AZA triplet shows favorable safety with no
1y agoAPTOAptose Announces First AML Patients Dosed with Tuspetinib Triplet Frontline Therapy in TUSCANY TrialGlobeNewswireSAN DIEGO and TORONTO, Jan. 09, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company, today announced dosing the first set of
1y agoAPTOAptose Announces Positive Decision by Nasdaq Hearings PanelGlobeNewswireSAN DIEGO and TORONTO, Dec. 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted
1y agoAPTOAptose Announces Publication of Preclinical Data in AACR Journal Demonstrating Tuspetinib's Unique Mechanism of Action and Synthetic Lethality on AML Cells When Combined with VenetoclaxGlobeNewswirePeer-reviewed publication details unique TUS mechanism of action TUS+VEN combination synthetic lethality overcomes resistance to VEN Tuspetinib prolongs survival in multiple AML models resistant to other drugs
1y agoAPTOAptose Clinical Data Featured in Poster Presentation at the 2024 ASH Annual Meeting Support Tuspetinib Triple Drug Therapy for Newly Diagnosed AMLGlobeNewswireTUS+VEN+AZA Triplet Frontline Therapy in Newly Diagnosed AML Patients Now Enrolling at U.S. SitesTUS and TUS+VEN Broadly Active Across AML Populations, with Favorable SafetyTUS-based therapies are active in FLT3
1y agoAPTOAptose Signs CRADA with NCI to Develop Tuspetinib for AML and MDS in Newly Launched MyeloMATCH Precision Medicine TrialsGlobeNewswireTuspetinib selected for a prestigious national clinical research program for ability to target broad spectrum of AML and MDS populations Trials to test tuspetinib in targeted drug combinations for frontline therapy of
1y agoAPTOAptose Biosciences Inc. Announces Closing of $8 Million Public OfferingGlobeNewswireSAN DIEGO and TORONTO, Nov. 25, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
1y agoAPTOAptose Biosciences Inc. Announces Pricing of $8 Million Public OfferingGlobeNewswireSAN DIEGO and TORONTO, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
1y agoAPTOAptose Initiates TUSCANY Phase 1/2 Study for Newly Diagnosed AML Patients to Receive Tuspetinib-based Triplet TherapyGlobeNewswireTUSCANY study is open to enroll patients to receive TUS+VEN+AZA triplet at select US sitesFavorable safety and broad clinical activity make tuspetinib an ideal agent to combine with venetoclax and azacitidine to
2y agoAPTOAptose Reports Results for the Third Quarter 2024GlobeNewswireSAN DIEGO and TORONTO, Nov. 08, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
2y agoAPTOAptose Announces Results from Special Meeting of ShareholdersGlobeNewswireSAN DIEGO and TORONTO, Sept. 05, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing tuspetinib, a highly
2y agoAPTOAptose Receives $10 Million Through a Facility Agreement with Hanmi; Negotiating Future Collaboration Agreement with Hanmi to Jointly Develop TuspetinibGlobeNewswireSAN DIEGO and TORONTO, Aug. 30, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing tuspetinib, a highly
2y agoAPTOAptose Announces Adjournment of its Special Meeting of ShareholdersGlobeNewswireSAN DIEGO and TORONTO, Aug. 15, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
2y agoAPTOAptose Reports Results for the Second Quarter 2024GlobeNewswireTUS+VEN+HMA Triplet Protocol in Frontline Therapy for Newly Diagnosed AML was Reviewed by the FDA and Allowed to Proceed Abstract Supporting Exploration of the TUS+VEN+AZA Triplet in Frontline Therapy for Newly
2y agoAPTONodThera Announces Appointment of Greg Chow as Chief Financial and Business OfficerGlobeNewswireNodThera Announces Appointment of Greg Chow as Chief Financial and Business Officer Greg brings over 25 years of public and private company leadership experience Philadelphia, PA, August 1, 2024 - NodThera, a leading
2y agoAPTOAptose Announces Receipt of Deficiency Notice from NasdaqGlobeNewswireSAN DIEGO and TORONTO, July 19, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
2y agoAPTOAptose Announces Results from Annual and Special Meeting of ShareholdersGlobeNewswireSAN DIEGO and TORONTO, June 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
2y agoAPTOAptose Presents Tuspetinib (TUS) Clinical and Preclinical Findings at European Hematology Association (EHA) 2024 Hybrid CongressGlobeNewswireTUS Monotherapy and TUS+Venetoclax (VEN) Doublet Therapy Show Broad Clinical Activity and Strong Safety Data in relapsed or refractory (R/R) Acute Myeloid Leukemia (AML) and Differentiate TUS from other Investigational
2y agoAPTOAptose Announces Closing of $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireSAN DIEGO and TORONTO, June 03, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
2y agoAPTOAptose Announces $4.43 Million Registered Direct Offering Priced At-the-Market Under Nasdaq RulesGlobeNewswireSAN DIEGO and TORONTO, May 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
2y agoAPTOAptose Biosciences Inc. (APTO) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
2y agoAPTOAptose Reports Results for the First Quarter 2024GlobeNewswireTUS+VEN+HMA Triplet Protocol in 1L Therapy for Newly Diagnosed AML was Submitted to the FDA During Q1 and is Now Being Activated at Clinical Sites TUS+VEN+HMA Triplet 1L Therapy for Newly Diagnosed AML is Supported by
2y agoAPTOAptose to Report First Quarter 2024 Financial Results and Provide Clinical Strategy Update on Tuesday, May 14, 2024GlobeNewswireSAN DIEGO and TORONTO, May 06, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat
2y agoAPTOAptose Biosciences Inc. (APTO) Q4 2023 Earnings Call TranscriptEarnings Call Transcripts
2y agoAPTOAptose Reports Results for the Fourth Quarter and Full Year 2023GlobeNewswireTuspetinib to Advance to TUS+VEN+HMA Triplet Therapy Pilot Study in 1L AMLTuspetinib Continues Broad Activity Across Mutations with Excellent Safety ProfileLuxeptinib G3 Formulation Achieves Desired Levels and Positions
2y agoAPTOAptose to Report Fourth Quarter and Year End 2023 Financial Results and Provide Corporate Update on Tuesday, March 26, 2024GlobeNewswireSAN DIEGO and TORONTO, March 18, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical- stage precision oncology company developing highly differentiated oral targeted agents to treat
2y agoAPTOAptose Announces Closing of $9.7 Million Public Offering and Concurrent $4 Million Private Placement with Hanmi Pharmaceutical, Including Full Exercise of Over-Allotment OptionGlobeNewswireSAN DIEGO and TORONTO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated
2y agoAPTOAptose Announces Pricing of $8.4 Million Public Offering and a Concurrent $4 Million Private Placement with Hanmi PharmaceuticalGlobeNewswireSAN DIEGO and TORONTO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted
2y agoAPTOAptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual MeetingGlobeNewswireReporting Complete Response Data from the Ongoing APTIVATE International Phase 1/2 Study of Tuspetinib (TUS) in Relapsed/Refractory AML PatientsTUS Single Agent and TUS/VEN Combination Demonstrate Favorable Safety and
2y agoAPTOAptose Appoints Fletcher Payne Chief Business Officer, Expanding his Executive RoleGlobeNewswireSAN DIEGO and TORONTO, Nov. 30, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
3y agoAPTOAptose Reports Results for the Third Quarter 2023GlobeNewswireTuspetinib (TUS) Targets Venetoclax (VEN) Resistance MechanismsTUS/VEN Combination Therapy Active in R/R VEN Failure AML Patients – Guides Toward Accelerated Approval Path, Including FLT3 Mutated and Wildtype TUS/VEN
3y agoAPTOAptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual MeetingGlobeNewswireSAN DIEGO and TORONTO, Nov. 02, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated targeted
3y agoAPTOAptose Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug TuspetinibGlobeNewswireTuspetinib (TUS) Combination with Venetoclax (VEN) Clinical Findings Highlighted TUS Targets VEN Resistance Mechanisms to Re-sensitize VEN Failure Patients to VEN44% ORR with TUS/VEN in Difficult-to-Treat VEN Failure
3y agoAPTOAptose to Report Third Quarter 2023 Financial Results and Hold Conference Call on Thursday, November 9, 2023GlobeNewswireSAN DIEGO and TORONTO, Oct. 26, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat
3y agoAPTOAptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30thGlobeNewswireSAN DIEGO and TORONTO, Oct. 23, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
3y agoAPTOAptose Clinical and Preclinical Data to be Presented at European School of Haematology (ESH) 6th International ConferenceGlobeNewswireSAN DIEGO and TORONTO, Oct. 16, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
3y agoAPTOAptose to Present at the Cantor Global Healthcare ConferenceGlobeNewswireSAN DIEGO and TORONTO, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
3y agoAPTOAptose Announces Closing of $3 Million Investment by Hanmi PharmaceuticalGlobeNewswireSAN DIEGO and TORONTO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
3y agoAPTOAptose to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceGlobeNewswireSAN DIEGO and TORONTO, Aug. 24, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral
3y agoAPTOAptose Reports Results for the Second Quarter 2023GlobeNewswire─ CRc Response Rate 50% with Tuspetinib/Venetoclax Doublet in Evaluable Patients ─ ─ CRc 44% in Patients Who Failed Prior Venetoclax ── CRc 43% in Patients with Wildtype FLT3 ── CRc 67% in Patients with
3y agoAPTOAptose to Report Second Quarter 2023 Financial Results and Hold Conference Call on Thursday, August 10, 2023GlobeNewswireSAN DIEGO and TORONTO, July 27, 2023 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ:APTO, TSX:APS), a clinical-stage precision oncology company developing highly differentiated oral targeted agents to treat